On December 11, 2018, the Food and Drug Administrative (“FDA”) issued a draft guidance for comment entitled, “Biomarker Qualification: Evidentiary Framework” (the “Guidance”). The Guidance provides insight regarding standards for biomarker qualification under the 21st Century Cures Act (“Cures Act”).
FDA defines the term “biomarker” as a “characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions.” There are various ...
Blog Editors
Recent Updates
- Closer Look at H.R. 7291: What the “GRAS Oversight and Transparency Act” Could Mean for Dietary Supplements
- Diagnostic Imaging Interoperability Request for Information Shines a Spotlight on the Lack of Patient-Centered Longitudinal Health Records
- DOJ Deputy Assistant Attorney General Addresses FCA Enforcement Priorities and Reinforces Commitment to Robust Enforcement
- Interested in Opening a Medical Spa? (Part III): Here’s (More) That You Need to Know
- IRS Issues Guidance Regarding Group Exemption Letters